The Delhi High Court upheld the validity of Novartis’s Ceritinib patent against Natco’s challenge, addressing divisional application issues and allegations of suppression. The injunction against Natco remains in force, reinforcing the enforceability of Novartis’s patent rights.
Read more about Revisiting Novartis versus Natco – Cancer drugs, divisional applications and patent validityTag: Novartis
Novartis says No to Novarish
The Bombay High Court granted Novartis an injunction against Novarish Healthcare for trademark infringement and passing off. The court found the marks deceptively similar and protected Novartis’s established rights under Indian IP law.
Read more about Novartis says No to NovarishCancerous Battle: Novartis and NATCO clash over Eltrombopag
The Delhi High Court Division Bench set aside an injunction against Natco Pharma in the Novartis Eltrombopag patent dispute. The judgment provides key guidance on patent validity challenges and the requirements under Section 3(d) of the Patents Act in pharmaceutical cases.
Read more about Cancerous Battle: Novartis and NATCO clash over EltrombopagProfiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents
This post explores how drug manufacturers leverage secondary patents to manage the patent cliff and maintain exclusivity. A detailed analysis of Entresto’s patent timeline and Indian legal context is provided.
Read more about Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary PatentsLatest Patent & Design Updates – January 2022 – Part 1
The post analyses significant patent and design updates for January 2022, focusing on India’s WTO patent waiver request and RGNIIPM’s training initiative. It also highlights major international patent developments and US court rulings.
Read more about Latest Patent & Design Updates – January 2022 – Part 1Latest Patent Cases in 2021 – Part 3
This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity, scope, and interim injunctions in Indian pharmaceutical and agricultural sectors.
Read more about Latest Patent Cases in 2021 – Part 3Novartis Trademark JALRA to be acquired for 200 crores, Private Company Acquires .Org Registry and more
USV Pvt Ltd will acquire the JALRA trademark from Novartis for 200 crores as the patent for Vildagliptin expires. The bulletin also discusses major updates in domain name disputes, brand licensing, and the GI tag awarded to Khola Chilli.
Read more about Novartis Trademark JALRA to be acquired for 200 crores, Private Company Acquires .Org Registry and moreNovartis Case Review
The Supreme Court’s Novartis judgment clarified Section 3d and its application to pharmaceutical patents in India. It emphasised the need for enhanced therapeutic efficacy and outlined critical standards for patentability, impacting future patent filings.
Read more about Novartis Case ReviewVoting Machine Patent, Delhi High Court restrains Natco, Samsung and Huawei settle patent dispute and more
The latest patent news analyses trends in Indian patent filings and grants, key court orders, and major patent settlements. It includes updates on the voting machine patent, Novartis’s litigation, and industry statistics.
Read more about Voting Machine Patent, Delhi High Court restrains Natco, Samsung and Huawei settle patent dispute and more